NINJ1 targeting shows potential for multiple sclerosis and other neurological conditions but faces significant knowledge gaps
NINJ1 targeting shows promise for multiple sclerosis and other brain injuries
This narrative review examines NINJ1 targeting as a therapeutic strategy for multiple sclerosis, ischemic stroke, traumatic brain injury, sp…
A review suggests NINJ1 targeting could help treat multiple sclerosis, stroke, and other brain injuries, though more research is needed.
Xatmep receives FDA approval for pediatric acute lymphoblastic leukemia and polyarticular juvenile idiopathic arthritis
FDA approves Xatmep for pediatric leukemia and arthritis treatment options
The FDA has approved Xatmep for pediatric patients with acute lymphoblastic leukemia or active polyarticular juvenile idiopathic arthritis. …
The FDA has approved Xatmep to treat specific forms of childhood leukemia and arthritis, offering new options for young patients.
Reduced-intensity ATRA plus arsenic with GO or low-dose anthracycline improves event-free survival in high-risk APL
New analysis shows reduced-intensity treatment works well for high-risk leukemia patients compared to standard intensive chemotherapy
This systematic review and meta-analysis of 1,323 patients with high-risk acute promyelocytic leukemia found that reduced-intensity inductio…
A large review of over 1,300 patients found that a gentler treatment plan worked just as well as harsher chemotherapy. This approach may hel…
Clinical and laboratory abnormalities linked to higher mortality in malaria patients with acute kidney injury
Severe lab changes in malaria patients with kidney injury strongly predict death
This systematic review and meta-analysis evaluated the relationship between various clinical and laboratory abnormalities and mortality in m…
Severe lab changes like low blood pressure or breathing trouble in malaria patients with kidney injury greatly increase the risk of dying.
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies
Idiotype-directed CAAR-T therapy remains a hypothesis for B-cell malignancies
This narrative review discusses idiotype-directed CAAR-T therapy for B-cell malignancies including chronic lymphocytic leukemia and indolent…
A narrative review suggests idiotype-directed CAAR-T therapy is a theoretical option for B-cell cancers, not a current treatment.
FDA Approves Venclexta (venetoclax) for CLL/SLL and AML
FDA approves new drug Venclexta for certain blood cancers
FDA approved Venclexta (venetoclax) for adult patients with CLL or SLL, and in combination with azacitidine, decitabine, or low-dose cytarab…
The FDA approved Venclexta (venetoclax) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is also a…
FDA Approves Argatroban for Thrombosis in Heparin-Induced Thrombocytopenia
FDA approves Argatroban to treat blood clots in patients with HIT
The FDA approved argatroban for prophylaxis or treatment of thrombosis in adult patients with heparin-induced thrombocytopenia (HIT) and as …
The FDA approved Argatroban to prevent or treat blood clots in adults with heparin-induced thrombocytopenia (HIT), a condition where heparin…
TEG-ROTEM guided transfusion may lower death and bleeding in cardiac surgery
New blood management tools may lower death risk during heart surgery, but proof is weak
A systematic review finds TEG-ROTEM guided transfusion may reduce mortality and bleeding in elective cardiac surgery, but evidence certainty…
A review suggests new blood tests could reduce death and bleeding during heart surgery, yet the evidence remains very uncertain and mostly c…
Scoping review examines imatinib gonadotoxicity in males with chronic myeloid leukemia or gastrointestinal stromal tumors
Young Men's Fertility at Risk with Common Cancer Drug Imatinib
This scoping review synthesizes evidence on imatinib effects in males with chronic myeloid leukemia or gastrointestinal stromal tumors. Twen…
• Imatinib harms sperm production more in younger men permanently • Helps doctors counsel teens and young adults before treatment • Not a tr…
FDA Approves Inqovi (decitabine/cedazuridine) for Myelodysplastic Syndromes
FDA approves new oral drug Inqovi for certain blood cancers.
FDA approved Inqovi (decitabine 35 mg/cedazuridine 100 mg) for adults with MDS, including CMML and intermediate-1, intermediate-2, and high-…
The FDA approved Inqovi, a pill that combines two drugs, for adults with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia…
Network meta-analysis of 107 RCTs on blood-invigorating Chinese herbal medicines for endometriosis
Chinese herbal medicines plus standard care help treat endometriosis better than standard care alone
This network meta-analysis synthesizes data from 107 RCTs evaluating blood-invigorating and stasis-resolving Chinese herbal medicines plus c…
A review of many studies shows adding specific Chinese herbs to standard treatment helps more women with endometriosis. Patients felt less p…
Delphi guideline on Para athletics talent identification and development strategies
Experts agree on best ways to find and train talented para athletes through surveys
This Delphi survey guideline synthesizes expert consensus on best practices for talent identification and development in Para athletics. The…
Twenty-three experts reviewed talent identification methods for para athletics. They agreed on using performance tests, personalized plans, …